Donald L Bliwise1, Rebecca H Zhang2, Nancy G Kutner2. 1. United States Renal Data System Rehabilitation/Quality of Life Special Studies Center and Department of Neurology, Emory University, Atlanta, GA, USA. Electronic address: dbliwis@emory.edu. 2. United States Renal Data System Rehabilitation/Quality of Life Special Studies Center and Department of Neurology, Emory University, Atlanta, GA, USA.
Abstract
OBJECTIVE: The objective of this study was to determine the association between the usage of four classes of "at-risk" medications (antidepressants, neuroleptics, antihistamines, and antiemetics with dopamine blockade) and restless legs syndrome (RLS) in dialysis patients within the United States Renal Data System (USRDS). METHODS: This was a case-control design within a national (United States) patient registry of all patients with end-stage renal disease (ESRD) in the USRDS anytime during the period of 1 October 2006 to 31 December 2010, inclusive. A total of 16,165 ESRD patients (3234 cases; 12,931 age-, sex-, and race-matched controls) were studied. RESULTS: All four classes of "at-risk" medications see widespread use among patients in the USRDS. All were associated with increased odds of an RLS diagnosis (range of odds ratios, 1.47-2.28; all p < 0.0001) during the period of observation. Results were unchanged when controlling for time on hemodialysis. Usage of more than one class of medication increased the odds for having RLS. CONCLUSIONS: ESRD patients often receive medication intended for relief of conditions associated with their disease, such as depression and psychological issues, pruritus, and gastroparesis; however, such medications may increase the risk of RLS. Given the high prevalence of RLS in ESRD patients, these medications should only be used when their benefits clearly outweigh the risk of development of the troubling and distressing symptoms of RLS.
OBJECTIVE: The objective of this study was to determine the association between the usage of four classes of "at-risk" medications (antidepressants, neuroleptics, antihistamines, and antiemetics with dopamine blockade) and restless legs syndrome (RLS) in dialysis patients within the United States Renal Data System (USRDS). METHODS: This was a case-control design within a national (United States) patient registry of all patients with end-stage renal disease (ESRD) in the USRDS anytime during the period of 1 October 2006 to 31 December 2010, inclusive. A total of 16,165 ESRDpatients (3234 cases; 12,931 age-, sex-, and race-matched controls) were studied. RESULTS: All four classes of "at-risk" medications see widespread use among patients in the USRDS. All were associated with increased odds of an RLS diagnosis (range of odds ratios, 1.47-2.28; all p < 0.0001) during the period of observation. Results were unchanged when controlling for time on hemodialysis. Usage of more than one class of medication increased the odds for having RLS. CONCLUSIONS:ESRDpatients often receive medication intended for relief of conditions associated with their disease, such as depression and psychological issues, pruritus, and gastroparesis; however, such medications may increase the risk of RLS. Given the high prevalence of RLS in ESRDpatients, these medications should only be used when their benefits clearly outweigh the risk of development of the troubling and distressing symptoms of RLS.
Authors: Carlos Martinez; Henrik Walter Finnern; Stephan Rietbrock; Susan Eaton; Kallol Ray Chaudhuri; Anthony H V Schapira Journal: Clin Ther Date: 2008-02 Impact factor: 3.393
Authors: Félix Javier Jiménez-Jiménez; Elena García-Martín; Hortensia Alonso-Navarro; Carmen Martínez; Martín Zurdo; Laura Turpín-Fenoll; Jorge Millán-Pascual; Teresa Adeva-Bartolomé; Esther Cubo; Francisco Navacerrada; Ana Rojo-Sebastián; Lluisa Rubio; Sara Ortega-Cubero; Pau Pastor; Marisol Calleja; José Francisco Plaza-Nieto; Belén Pilo-de-la-Fuente; Margarita Arroyo-Solera; Esteban García-Albea; José A G Agúndez Journal: J Neural Transm (Vienna) Date: 2016-11-11 Impact factor: 3.575
Authors: Kathy C Richards; Richard P Allen; Janet Morrison; Liam Fry; Christine R Kovach; Angelica Rangel; Ana Loera; Yanyan Wang; Alexandra L Hanlon; Alicia J Lozano; Donald L Bliwise Journal: J Am Med Dir Assoc Date: 2020-12-18 Impact factor: 7.802
Authors: Giuseppe Didato; Roberta Di Giacomo; Giuseppa Jolanda Rosa; Ambra Dominese; Marco de Curtis; Paola Lanteri Journal: Int J Environ Res Public Health Date: 2020-05-22 Impact factor: 3.390